TapewireFind a company

person · Reporting owner

Adams Brian

Disclosed activity across 3 companies

Tapewire entity
10235
SEC CIK
0001636994

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
KERYX BIOPHARMACEUTICALS INCKERX · Entity 161794General Counsel and SecretaryFebruary 15, 2018February 16, 2018
Kymera Therapeutics, Inc.KYMR · Entity 3545Chief Legal OfficerSeptember 04, 2026September 04, 2026
Relay Therapeutics, Inc.RLAY · Entity 4044Chief Legal OfficerJuly 28, 2025July 30, 2025

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

KERYX BIOPHARMACEUTICALS INC

Report date February 15, 2018 · Filed February 16, 2018

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect126,069 Reported balance After 2018-02-15 transaction · row 1 Account or security details depend on footnotes; rows are not merged.
1 source row

Row 1 · 2018-02-15 · Sale · Disposed 5,652 · Balance 126,069

F1: Sale of a total of 5,652 shares of common stock was made in order to satisfy Mr. Adams' income tax withholding obligation upon the vesting of 16,251 shares of restricted stock on February 14, 2018. Mr. Adams had no discretion with respect to such sale, which was transacted in accordance with the Issuer's corporate policies regarding the vesting of restricted stock.

F2: Includes 50,415 shares of restricted stock.

Filing footnotes · ownership attribution and instrument terms

F1: Sale of a total of 5,652 shares of common stock was made in order to satisfy Mr. Adams' income tax withholding obligation upon the vesting of 16,251 shares of restricted stock on February 14, 2018. Mr. Adams had no discretion with respect to such sale, which was transacted in accordance with the Issuer's corporate policies regarding the vesting of restricted stock.

F2: Includes 50,415 shares of restricted stock.

Kymera Therapeutics, Inc.

Report date September 04, 2026 · Filed September 04, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect50,254 Ending reported balance After 2026-09-04 transaction · row 3
3 source rows · reconciled sequence

Row 1 · 2026-09-04 · Sale · Disposed 1,209 · Balance 55,416

F1: Represents shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not in the discretion of the Reporting Person.

F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $115.09 to $116.08, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Row 2 · 2026-09-04 · Sale · Disposed 3,025 · Balance 52,391

F1: Represents shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not in the discretion of the Reporting Person.

F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $116.09 to $117.08, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Row 3 · 2026-09-04 · Sale · Disposed 2,137 · Balance 50,254

F1: Represents shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not in the discretion of the Reporting Person.

F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $117.38 to $117.85, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Filing footnotes · ownership attribution and instrument terms

F1: Represents shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not in the discretion of the Reporting Person.

F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $115.09 to $116.08, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $116.09 to $117.08, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $117.38 to $117.85, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Relay Therapeutics, Inc.

Report date July 28, 2025 · Filed July 30, 2025

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect389,748 Reported balance After 2025-07-28 transaction · row 1 Account or security details depend on footnotes; rows are not merged.
1 source row

Row 1 · 2025-07-28 · Sale · Disposed 1,637 · Balance 389,748

F1: Sale of shares to cover the reporting person's income tax withholding obligations upon the vesting of 5,506 shares of restricted stock units ("RSUs") on July 27, 2025. The reporting person had no discretion with respect to such sale, which was transacted in accordance with the Issuer's policies regarding the vesting of RSUs.

F2: Includes 187,004 shares underlying RSUs.

Common StockSEC Table I · non-derivativeDirect371,472 Reported balance After 2025-07-29 transaction · row 2 Account or security details depend on footnotes; rows are not merged.
1 source row

Row 2 · 2025-07-29 · Sale · Disposed 18,276 · Balance 371,472

F3: Sale of shares to cover the reporting person's income tax withholding obligations upon the vesting of 42,393 shares of RSUs on July 28, 2025. The reporting person had no discretion with respect to such sale, which was transacted in accordance with the Issuer's policies regarding the vesting of RSUs.

F4: Includes 144,611 shares underlying RSUs.

Filing footnotes · ownership attribution and instrument terms

F1: Sale of shares to cover the reporting person's income tax withholding obligations upon the vesting of 5,506 shares of restricted stock units ("RSUs") on July 27, 2025. The reporting person had no discretion with respect to such sale, which was transacted in accordance with the Issuer's policies regarding the vesting of RSUs.

F2: Includes 187,004 shares underlying RSUs.

F3: Sale of shares to cover the reporting person's income tax withholding obligations upon the vesting of 42,393 shares of RSUs on July 28, 2025. The reporting person had no discretion with respect to such sale, which was transacted in accordance with the Issuer's policies regarding the vesting of RSUs.

F4: Includes 144,611 shares underlying RSUs.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
November 15, 2021 Filed Nov 17, 2021 00:07 UTC Relay Therapeutics, Inc. RLAY · Entity 4044 SaleCommon Stock 6,500 $35.42 $230,230.00
Disclosure

SEC source: 0001209191-21-064872 · doc4.xml · nonDerivative · entry 2

Adams Brian · CIK 0001636994 · General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,284

F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 28, 2020.

F3 · price: This transaction was executed in multiple trades at prices ranging from $35.03 to $35.80. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

F2 · balance_after: Includes 13,887 shares underlying RSUs.

Read SEC document
November 15, 2021 Filed Nov 17, 2021 00:07 UTC Relay Therapeutics, Inc. RLAY · Entity 4044 Exercise / conversionCommon Stock 6,500 $4.12 $26,780.00
Disclosure

SEC source: 0001209191-21-064872 · doc4.xml · nonDerivative · entry 1

Adams Brian · CIK 0001636994 · General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 31,784

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 28, 2020.

F2 · balance_after: Includes 13,887 shares underlying RSUs.

Read SEC document
September 27, 2021 Filed Sep 28, 2021 01:21 UTC Relay Therapeutics, Inc. RLAY · Entity 4044 SaleCommon Stock 293 $36.87 $10,802.91
Disclosure

SEC source: 0001209191-21-057858 · doc4.xml · nonDerivative · entry 1

Adams Brian · CIK 0001636994 · General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,284

F1 · shares: Sale of shares to cover the reporting person's income tax withholding obligations upon the vesting of 992 shares of restricted stock units ("RSUs") on September 26, 2021. The reporting person had no discretion with respect to such sale, which was transacted in accordance with the Issuer's policies regarding the vesting of RSUs.

F2 · balance_after: Includes 13,887 shares underlying RSUs.

Read SEC document
September 13, 2021 Filed Sep 14, 2021 00:27 UTC Relay Therapeutics, Inc. RLAY · Entity 4044 Exercise / conversionStock Option (Right to Buy) · Derivative 6,500 $0.00 Strike: $4.12 $0.00
Disclosure

SEC source: 0001209191-21-055784 · doc4.xml · derivative · entry 3

Adams Brian · CIK 0001636994 · General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 147,286

Underlying: Common Stock · 6,500 shares

Expires 2028-03-22

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 28, 2020.

F3 · derivative.exercise_date: Twenty-five percent (25%) of the shares underlying this option vested on March 19, 2019 and the remainder shall vest in equal quarterly installments over the remaining thirty-six (36) months, subject to the reporting person's continued employment through each vesting date.

Read SEC document
September 13, 2021 Filed Sep 14, 2021 00:27 UTC Relay Therapeutics, Inc. RLAY · Entity 4044 SaleCommon Stock 6,500 $35.02 $227,630.00
Disclosure

SEC source: 0001209191-21-055784 · doc4.xml · nonDerivative · entry 2

Adams Brian · CIK 0001636994 · General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,577

F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 28, 2020.

F2 · price: This transaction was executed in multiple trades at prices ranging from $35.00 to $35.03. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

Read SEC document
September 13, 2021 Filed Sep 14, 2021 00:27 UTC Relay Therapeutics, Inc. RLAY · Entity 4044 Exercise / conversionCommon Stock 6,500 $4.12 $26,780.00
Disclosure

SEC source: 0001209191-21-055784 · doc4.xml · nonDerivative · entry 1

Adams Brian · CIK 0001636994 · General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 32,077

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 28, 2020.

Read SEC document
June 28, 2021 Filed Jun 30, 2021 22:28 UTC Relay Therapeutics, Inc. RLAY · Entity 4044 SaleCommon Stock 293 $35.81 $10,492.33
Disclosure

SEC source: 0001209191-21-044065 · doc4.xml · nonDerivative · entry 1

Adams Brian · CIK 0001636994 · General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,577

F1 · shares: Sale of shares to cover the reporting person's income tax withholding obligations upon the vesting of 991 shares of restricted stock units ("RSUs") on June 26, 2021. The reporting person had no discretion with respect to such sale, which was transacted in accordance with the Issuer's policies regarding the vesting of RSUs.

F2 · balance_after: Includes 14,879 shares underlying RSUs.

Read SEC document
June 07, 2021 Filed Jun 10, 2021 00:37 UTC Relay Therapeutics, Inc. RLAY · Entity 4044 Exercise / conversionStock Option (Right to Buy) · Derivative 6,500 $0.00 Strike: $4.12 $0.00
Disclosure

SEC source: 0001209191-21-039328 · doc4.xml · derivative · entry 3

Adams Brian · CIK 0001636994 · General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 153,786

Underlying: Common Stock · 6,500 shares

Expires 2028-03-22

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 28, 2020.

F2 · derivative.exercise_date: Twenty-five percent (25%) of the shares underlying this option vested on March 19, 2019 and the remainder shall vest in equal quarterly installments over the remaining thirty-six (36) months, subject to the reporting person's continued employment through each vesting date.

Read SEC document
June 07, 2021 Filed Jun 10, 2021 00:37 UTC Relay Therapeutics, Inc. RLAY · Entity 4044 SaleCommon Stock 6,500 $35.00 $227,500.00
Disclosure

SEC source: 0001209191-21-039328 · doc4.xml · nonDerivative · entry 2

Adams Brian · CIK 0001636994 · General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,870

F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 28, 2020.

Read SEC document
June 07, 2021 Filed Jun 10, 2021 00:37 UTC Relay Therapeutics, Inc. RLAY · Entity 4044 Exercise / conversionCommon Stock 6,500 $4.12 $26,780.00
Disclosure

SEC source: 0001209191-21-039328 · doc4.xml · nonDerivative · entry 1

Adams Brian · CIK 0001636994 · General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 32,370

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 28, 2020.

Read SEC document
April 26, 2021 Filed Apr 29, 2021 01:15 UTC Relay Therapeutics, Inc. RLAY · Entity 4044 Exercise / conversionStock Option (Right to Buy) · Derivative 6,500 $0.00 Strike: $4.12 $0.00
Disclosure

SEC source: 0001209191-21-028861 · doc4.xml · derivative · entry 3

Adams Brian · CIK 0001636994 · General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 160,286

Underlying: Common Stock · 6,500 shares

Expires 2028-03-22

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 28, 2020.

F2 · derivative.exercise_date: Twenty-five percent (25%) of the shares underlying this option vested on March 19, 2019 and the remainder shall vest in equal quarterly installments over the remaining thirty-six (36) months, subject to the reporting person's continued employment through each vesting date.

Read SEC document
April 26, 2021 Filed Apr 29, 2021 01:15 UTC Relay Therapeutics, Inc. RLAY · Entity 4044 SaleCommon Stock 6,500 $35.00 $227,500.00
Disclosure

SEC source: 0001209191-21-028861 · doc4.xml · nonDerivative · entry 2

Adams Brian · CIK 0001636994 · General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,870

F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 28, 2020.

Read SEC document
April 26, 2021 Filed Apr 29, 2021 01:15 UTC Relay Therapeutics, Inc. RLAY · Entity 4044 Exercise / conversionCommon Stock 6,500 $4.12 $26,780.00
Disclosure

SEC source: 0001209191-21-028861 · doc4.xml · nonDerivative · entry 1

Adams Brian · CIK 0001636994 · General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 32,370

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 28, 2020.

Read SEC document
March 26, 2021 Filed Mar 26, 2021 23:59 UTC Relay Therapeutics, Inc. RLAY · Entity 4044 GrantStock Option (Right to Buy) · Derivative 31,740 $0.00 Strike: $34.25 $0.00
Disclosure

SEC source: 0001209191-21-023331 · doc4.xml · derivative · entry 2

Adams Brian · CIK 0001636994 · General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 31,740

Underlying: Common Stock · 31,740 shares

Expires 2031-03-25

F2 · derivative.exercise_date: The shares underlying this stock option shall vest in sixteen (16) equal quarterly installments after March 26, 2021, subject to the reporting person's continued service with the Issuer through each vesting date.

Read SEC document
March 26, 2021 Filed Mar 26, 2021 23:59 UTC Relay Therapeutics, Inc. RLAY · Entity 4044 GrantCommon Stock 15,870 $0.00 $0.00
Disclosure

SEC source: 0001209191-21-023331 · doc4.xml · nonDerivative · entry 1

Adams Brian · CIK 0001636994 · General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,870

F1 · shares: Represents restricted stock units ("RSUs") granted to the reporting person pursuant to the Issuer's 2020 Stock Option and Incentive Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock upon vesting. The RSUs shall vest in sixteen (16) equal quarterly installments after March 26, 2021, subject to the reporting person's continued service with the Issuer through each vesting date.

Read SEC document
January 28, 2021 Filed Jan 30, 2021 02:00 UTC Relay Therapeutics, Inc. RLAY · Entity 4044 Exercise / conversionStock Option (Right to Buy) · Derivative 5,000 $0.00 Strike: $4.12 $0.00
Disclosure

SEC source: 0001209191-21-006365 · doc4.xml · derivative · entry 3

Adams Brian · CIK 0001636994 · General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 166,786

Underlying: Common Stock · 5,000 shares

Expires 2028-03-22

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: Twenty-five percent (25%) of the shares underlying this option vested on March 19, 2019 and the remainder shall vest in equal quarterly installments over the remaining thirty-six (36) months, subject to the reporting person's continued employment through each vesting date.

Read SEC document
January 28, 2021 Filed Jan 30, 2021 02:00 UTC Relay Therapeutics, Inc. RLAY · Entity 4044 SaleCommon Stock 5,000 $55.05 $275,250.00
Disclosure

SEC source: 0001209191-21-006365 · doc4.xml · nonDerivative · entry 2

Adams Brian · CIK 0001636994 · General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,000

F1 · price: This transaction was executed in multiple trades at prices ranging from $55.00 to $55.24. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

Read SEC document
January 28, 2021 Filed Jan 30, 2021 02:00 UTC Relay Therapeutics, Inc. RLAY · Entity 4044 Exercise / conversionCommon Stock 5,000 $4.12 $20,600.00
Disclosure

SEC source: 0001209191-21-006365 · doc4.xml · nonDerivative · entry 1

Adams Brian · CIK 0001636994 · General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
December 11, 2020 Filed Dec 15, 2020 21:30 UTC Relay Therapeutics, Inc. RLAY · Entity 4044 GrantStock Option (Right to Buy) · Derivative 67,588 $0.00 Strike: $5.22 $0.00
Disclosure

SEC source: 0001209191-20-063480 · doc4.xml · derivative · entry 1

Adams Brian · CIK 0001636994 · General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 67,588

Underlying: Common Stock · 67,588 shares

Expires 2030-03-01

F1 · shares: On March 2, 2020, the reporting person was granted an option to purchase 67,588 shares of common stock, subject to determination by the Board of Directors of the Issuer (the "Board") that the Issuer has met, in whole or in part, certain milestones (the "2020 Option Grant Criteria"). On June 23, 2020, the Board determined that the 2020 Option Grant Criteria related to 25% of the option had been achieved, and the shares underlying 25% of this option, or 16,897 shares, commenced vesting in sixteen (16) equal quarterly installments following September 23, 2020. On December 11, 2020, the Board determined that the 2020 Option Grant Criteria related to the remaining 75% of the option had been achieved. The shares underlying 75% of this option, or 50,691 shares, shall vest in sixteen (16) equal quarterly installments following March 11, 2021. Vesting of this option is subject to the reporting person's continued employment through each applicable vesting date.

F1 · derivative.exercise_date: On March 2, 2020, the reporting person was granted an option to purchase 67,588 shares of common stock, subject to determination by the Board of Directors of the Issuer (the "Board") that the Issuer has met, in whole or in part, certain milestones (the "2020 Option Grant Criteria"). On June 23, 2020, the Board determined that the 2020 Option Grant Criteria related to 25% of the option had been achieved, and the shares underlying 25% of this option, or 16,897 shares, commenced vesting in sixteen (16) equal quarterly installments following September 23, 2020. On December 11, 2020, the Board determined that the 2020 Option Grant Criteria related to the remaining 75% of the option had been achieved. The shares underlying 75% of this option, or 50,691 shares, shall vest in sixteen (16) equal quarterly installments following March 11, 2021. Vesting of this option is subject to the reporting person's continued employment through each applicable vesting date.

F1 · derivative.underlying_shares: On March 2, 2020, the reporting person was granted an option to purchase 67,588 shares of common stock, subject to determination by the Board of Directors of the Issuer (the "Board") that the Issuer has met, in whole or in part, certain milestones (the "2020 Option Grant Criteria"). On June 23, 2020, the Board determined that the 2020 Option Grant Criteria related to 25% of the option had been achieved, and the shares underlying 25% of this option, or 16,897 shares, commenced vesting in sixteen (16) equal quarterly installments following September 23, 2020. On December 11, 2020, the Board determined that the 2020 Option Grant Criteria related to the remaining 75% of the option had been achieved. The shares underlying 75% of this option, or 50,691 shares, shall vest in sixteen (16) equal quarterly installments following March 11, 2021. Vesting of this option is subject to the reporting person's continued employment through each applicable vesting date.

F1 · balance_after: On March 2, 2020, the reporting person was granted an option to purchase 67,588 shares of common stock, subject to determination by the Board of Directors of the Issuer (the "Board") that the Issuer has met, in whole or in part, certain milestones (the "2020 Option Grant Criteria"). On June 23, 2020, the Board determined that the 2020 Option Grant Criteria related to 25% of the option had been achieved, and the shares underlying 25% of this option, or 16,897 shares, commenced vesting in sixteen (16) equal quarterly installments following September 23, 2020. On December 11, 2020, the Board determined that the 2020 Option Grant Criteria related to the remaining 75% of the option had been achieved. The shares underlying 75% of this option, or 50,691 shares, shall vest in sixteen (16) equal quarterly installments following March 11, 2021. Vesting of this option is subject to the reporting person's continued employment through each applicable vesting date.

Read SEC document
July 20, 2020 Filed Jul 21, 2020 23:15 UTC Relay Therapeutics, Inc. RLAY · Entity 4044 PurchaseCommon Stock 10,000 $20.00 $200,000.00
Disclosure

SEC source: 0000899243-20-019840 · doc4.xml · nonDerivative · entry 1

Adams Brian · CIK 0001636994 · General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,000

F1 · price: On July 20, 2020, the Reporting Person purchased 10,000 shares of common stock, par value $0.001 per share, of the Issuer at a price of $20.00 per share pursuant to an underwritten public offering.

Read SEC document
February 15, 2018 Filed Feb 16, 2018 16:04 UTC KERYX BIOPHARMACEUTICALS INC KERX · Entity 161794 SaleCommon Stock 5,652 $4.81 $27,186.12
Disclosure

SEC source: 0001114220-18-000021 · wf-form4_151881503397408.xml · nonDerivative · entry 1

Adams Brian · CIK 0001636994 · General Counsel and Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 126,069

F1 · price: Sale of a total of 5,652 shares of common stock was made in order to satisfy Mr. Adams' income tax withholding obligation upon the vesting of 16,251 shares of restricted stock on February 14, 2018. Mr. Adams had no discretion with respect to such sale, which was transacted in accordance with the Issuer's corporate policies regarding the vesting of restricted stock.

F2 · balance_after: Includes 50,415 shares of restricted stock.

Read SEC document
January 29, 2018 Filed Jan 31, 2018 17:18 UTC KERYX BIOPHARMACEUTICALS INC KERX · Entity 161794 SaleCommon Stock 1,541 $4.81 $7,412.21
Disclosure

SEC source: 0001114220-18-000013 · wf-form4_151743711456240.xml · nonDerivative · entry 1

Adams Brian · CIK 0001636994 · General Counsel and Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 131,721

F1 · price: Sale of a total of 1,541 shares of common stock was made in order to satisfy Mr. Adams' income tax withholding obligation upon the vesting of 4,479 shares of restricted stock on January 26, 2018. Mr. Adams had no discretion with respect to such sale, which was transacted in accordance with the Issuer's corporate policies regarding the vesting of restricted stock.

F2 · balance_after: Includes 66,666 shares of restricted stock.

Read SEC document
January 05, 2018 Filed Jan 8, 2018 18:06 UTC KERYX BIOPHARMACEUTICALS INC KERX · Entity 161794 SaleCommon Stock 753 $4.69 $3,531.57
Disclosure

SEC source: 0001114220-18-000004 · wf-form4_151545276854523.xml · nonDerivative · entry 1

Adams Brian · CIK 0001636994 · General Counsel and Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 133,262

F1 · price: Sale of a total of 753 shares of common stock was made in order to satisfy Mr. Adams' income tax withholding obligation upon the vesting of 1,989 shares of restricted stock on January 4, 2018. Mr. Adams had no discretion with respect to such sale, which was transacted in accordance with the Issuer's corporate policies regarding the vesting of restricted stock.

F2 · balance_after: Includes 71,145 shares of restricted stock.

Read SEC document
October 30, 2017 Filed Oct 31, 2017 16:11 UTC KERYX BIOPHARMACEUTICALS INC KERX · Entity 161794 SaleCommon Stock 1,405 $6.03 $8,472.15
Disclosure

SEC source: 0001114220-17-000039 · wf-form4_150948067069170.xml · nonDerivative · entry 1

Adams Brian · CIK 0001636994 · General Counsel and Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 134,015

F1 · price: Sale of a total of 1,405 shares of common stock was made in order to satisfy Mr. Adams' income tax withholding obligation upon the vesting of 4,479 shares of restricted stock on October 27, 2017. Mr. Adams had no discretion with respect to such sale, which was transacted in accordance with the Issuer's corporate policies regarding the vesting of restricted stock.

F2 · balance_after: Includes 73,134 shares of restricted stock.

Read SEC document
October 05, 2017 Filed Oct 6, 2017 17:25 UTC KERYX BIOPHARMACEUTICALS INC KERX · Entity 161794 SaleCommon Stock 630 $7.19 $4,529.70
Disclosure

SEC source: 0001114220-17-000032 · wf-form4_150732510244312.xml · nonDerivative · entry 1

Adams Brian · CIK 0001636994 · General Counsel and Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 135,420

F1 · price: Sale of a total of 630 shares of common stock was made in order to satisfy Mr. Adams' income tax withholding obligation upon the vesting of 1,989 shares of restricted stock on October 4, 2017. Mr. Adams had no discretion with respect to such sale, which was transacted in accordance with the Issuer's corporate policies regarding the vesting of restricted stock.

F2 · balance_after: Includes 77,613 shares of restricted stock.

Read SEC document
July 31, 2017 Filed Aug 1, 2017 16:28 UTC KERYX BIOPHARMACEUTICALS INC KERX · Entity 161794 SaleCommon Stock 1,445 $7.14 $10,317.30
Disclosure

SEC source: 0001114220-17-000024 · wf-form4_150161932168614.xml · nonDerivative · entry 1

Adams Brian · CIK 0001636994 · General Counsel and Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 136,050

F1 · price: Sale of a total of 1,445 shares of common stock was made in order to satisfy Mr. Adams' income tax withholding obligation upon the vesting of 4,479 shares of restricted stock on July 28, 2017. Mr. Adams had no discretion with respect to such sale, which was transacted in accordance with the Issuer's corporate policies regarding the vesting of restricted stock.

F2 · balance_after: Includes 79,602 shares of restricted stock.

Read SEC document
July 05, 2017 Filed Jul 6, 2017 17:59 UTC KERYX BIOPHARMACEUTICALS INC KERX · Entity 161794 SaleCommon Stock 641 $7.67 $4,916.47
Disclosure

SEC source: 0000899243-17-018004 · doc4.xml · nonDerivative · entry 1

Adams Brian · CIK 0001636994 · General Counsel and Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 137,495

F1 · price: Sale of a total of 641 shares of common stock was made in order to satisfy Mr. Adams' income tax withholding obligation upon the vesting of 1,989 shares of restricted stock on July 3, 2017. Mr. Adams had no discretion with respect to such sale, which was transacted automatically in accordance with the Issuer's corporate policies regarding the vesting of restricted stock.

F2 · balance_after: Includes 84,081 shares of restricted stock.

Read SEC document
May 01, 2017 Filed May 3, 2017 16:05 UTC KERYX BIOPHARMACEUTICALS INC KERX · Entity 161794 SaleCommon Stock 1,441 $5.97 $8,602.77
Disclosure

SEC source: 0000899243-17-011609 · doc4.xml · nonDerivative · entry 1

Adams Brian · CIK 0001636994 · General Counsel and Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 138,136

F1 · price: Sale of a total of 1,441 shares of common stock was made in order to satisfy Mr. Adams' income tax withholding obligation upon the vesting of 4,480 shares of restricted stock on April 28, 2017. Mr. Adams had no discretion with respect to such sale, which was transacted automatically in accordance with the Issuer's corporate policies regarding the vesting of restricted stock.

F2 · balance_after: Includes 86,070 shares of restricted stock.

Read SEC document
April 17, 2017 Filed Apr 18, 2017 16:05 UTC KERYX BIOPHARMACEUTICALS INC KERX · Entity 161794 SaleCommon Stock 1,090 $5.75 $6,267.50
Disclosure

SEC source: 0000899243-17-010411 · doc4.xml · nonDerivative · entry 1

Adams Brian · CIK 0001636994 · General Counsel and Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 139,577

F1 · price: Sale of a total of 1,090 shares of common stock was made in order to satisfy Mr. Adams' income tax withholding obligation upon the vesting of 3,333 shares of restricted stock on April 14, 2017. Mr. Adams had no discretion with respect to such sale, which was transacted automatically in accordance with the Issuer's corporate policies regarding the vesting of restricted stock.

F2 · balance_after: Includes 90,550 shares of restricted stock.

Read SEC document
April 05, 2017 Filed Apr 6, 2017 16:05 UTC KERYX BIOPHARMACEUTICALS INC KERX · Entity 161794 SaleCommon Stock 642 $5.80 $3,723.60
Disclosure

SEC source: 0000899243-17-009647 · doc4.xml · nonDerivative · entry 1

Adams Brian · CIK 0001636994 · General Counsel and Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 140,667

F1 · price: Sale of a total of 642 shares of common stock was made in order to satisfy Mr. Adams' income tax withholding obligation upon the vesting of 1,989 shares of restricted stock on April 4, 2017. Mr. Adams had no discretion with respect to such sale, which was transacted automatically in accordance with the Issuer's corporate policies regarding the vesting of restricted stock.

F2 · balance_after: Includes 93,883 shares of restricted stock.

Read SEC document
February 14, 2017 Filed Mar 15, 2017 18:28 UTC KERYX BIOPHARMACEUTICALS INC KERX · Entity 161794 GrantEmployee Stock Option (Right to Buy) · Derivative 97,500 $0.00 Strike: $5.53 $0.00
Disclosure

SEC source: 0000899243-17-007646 · doc4.xml · derivative · entry 2

Adams Brian · CIK 0001636994 · General Counsel and Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 97,500

Underlying: Common Stock · 97,500 shares

Expires 2027-02-14

F3 · derivative.exercise_date: The options vest according to the following schedule: one-third of the 97,500 options will vest on February 14, 2018 and one-twelfth will vest on each of May 14, 2018, August 14, 2018, November 14, 2018, February 14, 2019, May 14, 2019, August 14, 2019, November 14, 2019 and February 14, 2020.

Read SEC document
February 14, 2017 Filed Mar 15, 2017 18:28 UTC KERYX BIOPHARMACEUTICALS INC KERX · Entity 161794 GrantCommon Stock 48,750 $0.00 $0.00
Disclosure

SEC source: 0000899243-17-007646 · doc4.xml · nonDerivative · entry 1

Adams Brian · CIK 0001636994 · General Counsel and Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 141,309

F1 · shares: The 48,750 shares are restricted common stock, with one-third of the 48,750 shares vesting on February 14, 2018 and one-twelfth vesting on each of May 14, 2018, August 14, 2018, November 14, 2018, February 14, 2019, May 14, 2019, August 14, 2019, November 14, 2019 and February 14, 2020.

F2 · balance_after: Includes 95,872 shares of restricted stock.

Read SEC document
January 30, 2017 Filed Jan 31, 2017 16:05 UTC KERYX BIOPHARMACEUTICALS INC KERX · Entity 161794 SaleCommon Stock 6,984 $4.65 $32,475.60
Disclosure

SEC source: 0000899243-17-002276 · doc4.xml · nonDerivative · entry 1

Adams Brian · CIK 0001636994 · General Counsel and Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 92,559

F1 · price: Sale of a total of 6,984 shares of common stock was made in order to satisfy Mr. Adams' income tax withholding obligation upon the vesting of 17,917 shares of restricted stock on January 27, 2017. Mr. Adams had no discretion with respect to such sale, which was transacted automatically in accordance with the Issuer's corporate policies regarding the vesting of restricted stock.

F2 · balance_after: Includes 47,122 shares of restricted stock.

Read SEC document
January 17, 2017 Filed Jan 18, 2017 16:05 UTC KERYX BIOPHARMACEUTICALS INC KERX · Entity 161794 SaleCommon Stock 1,265 $6.24 $7,893.60
Disclosure

SEC source: 0000899243-17-001438 · doc4.xml · nonDerivative · entry 1

Adams Brian · CIK 0001636994 · VP and General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 99,543

F1 · price: Sale of a total of 1,265 shares of common stock was made in order to satisfy Mr. Adams' income tax withholding obligation upon the vesting of 3,333 shares of restricted stock on January 14, 2017. Mr. Adams had no discretion with respect to such sale, which was transacted automatically in accordance with the Issuer's corporate policies regarding the vesting of restricted stock.

F2 · balance_after: Includes 65,039 shares of restricted stock.

Read SEC document
January 05, 2017 Filed Jan 6, 2017 16:06 UTC KERYX BIOPHARMACEUTICALS INC KERX · Entity 161794 SaleCommon Stock 759 $6.16 $4,675.44
Disclosure

SEC source: 0000899243-17-000674 · doc4.xml · nonDerivative · entry 1

Adams Brian · CIK 0001636994 · VP and General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 100,808

F1 · price: Sale of a total of 759 shares of common stock was made in order to satisfy Mr. Adams' income tax withholding obligation upon the vesting of 1,990 shares of restricted stock on January 4, 2017. Mr. Adams had no discretion with respect to such sale, which was transacted automatically in accordance with the Issuer's corporate policies regarding the vesting of restricted stock.

F2 · balance_after: Includes 68,372 shares of restricted stock.

Read SEC document
October 17, 2016 Filed Oct 18, 2016 16:05 UTC KERYX BIOPHARMACEUTICALS INC KERX · Entity 161794 SaleCommon Stock 1,106 $4.86 $5,375.16
Disclosure

SEC source: 0000899243-16-031825 · doc4.xml · nonDerivative · entry 1

Adams Brian · CIK 0001636994 · VP and General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 101,567

F1 · price: Sale of a total of 1,106 shares of common stock was made in order to satisfy Mr. Adams income tax withholding obligation upon the vesting of 3,333 shares of restricted stock on October 14, 2016. Mr. Adams had no discretion with respect to such sale, which was transacted automatically in accordance with the Issuer's corporate policies regarding the vesting of restricted stock.

F2 · balance_after: Includes 70,362 shares of restricted stock.

Read SEC document
October 05, 2016 Filed Oct 6, 2016 16:05 UTC KERYX BIOPHARMACEUTICALS INC KERX · Entity 161794 SaleCommon Stock 647 $5.38 $3,480.86
Disclosure

SEC source: 0000899243-16-031390 · doc4.xml · nonDerivative · entry 1

Adams Brian · CIK 0001636994 · VP and General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 102,673

F1 · price: Sale of a total of 647 shares of common stock was made in order to satisfy Mr. Adams' income tax withholding obligation upon the vesting of 1,990 shares of restricted stock on October 4, 2016. Mr. Adams had no discretion with respect to such sale, which was transacted automatically in accordance with the Issuer's corporate policies regarding the vesting of restricted stock.

F2 · balance_after: Includes 73,695 shares of restricted stock.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.